Free Trial
NASDAQ:CLNN

Clene Q4 2025 Earnings Results & Report

Clene logo
$4.04 +0.05 (+1.13%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Clene missed analyst earnings expectations but beat on revenue in its Q4 2025 results, released March 12, 2026. The company reported EPS of -$0.88 versus the -$0.74 consensus estimate, while revenue of $77 thousand topped the $30 thousand estimate by $47 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Clene EPS Results

Actual EPS
-$0.88
Consensus EPS
-$0.74
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Clene Revenue Results

Actual Revenue
$77 thousand
Expected Revenue
$30 thousand
Beat/Miss
Beat by +$47.00 thousand
YoY Revenue Growth
N/A

Clene Q4 2025 Earnings FAQ

Clene (NASDAQ:CLNN) reported earnings of -$0.88 per share for Q4 2025, missing the consensus estimate of -$0.74. The report was announced on Thursday, March 12, 2026.

Clene reported revenue of $77 thousand for Q4 2025, against a consensus estimate of $30 thousand.

Clene Earnings Headlines

Research Analysts Set Expectations for Clene FY2026 Earnings
This Could Be the Biggest Monetary Shift in 50 Years
The U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.tc pixel
Clene (NASDAQ:CLNN) Stock Lifted to Hold by Wall Street Zen
Clene (CLNN) Expected to Announce Earnings on Thursday
See More Clene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clene and other key companies, straight to your email.

About Clene

Clene (NASDAQ:CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells.

Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders. CNM-Au8 remains an investigational therapy and is not approved for general commercial use.

Founded in 2013, Clene is headquartered in Salt Lake City, Utah, and conducts its research and clinical development activities primarily through U.S.-based programs, while working with research and clinical collaborators as appropriate. The company is led by Chief Executive Officer Robert Etherington and trades on the Nasdaq under the symbol CLNN.

View Clene Profile